Gatifloxacin-1,2,3-triazole-isatin hybrids and their antimycobacterial activities.
Animals
Antitubercular Agents
/ chemical synthesis
CHO Cells
Cell Survival
/ drug effects
Cricetinae
Cricetulus
Drug Design
Drug Resistance, Multiple, Bacterial
/ drug effects
Gatifloxacin
/ chemistry
Isatin
/ chemistry
Microbial Sensitivity Tests
Molecular Structure
Mycobacterium tuberculosis
/ drug effects
Triazoles
/ chemical synthesis
1,2,3-triazole
antimycobacterial
antitubercular
gatifloxacin
isatin
multidrug resistant
Journal
Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
07
05
2019
revised:
18
07
2019
accepted:
23
07
2019
pubmed:
24
8
2019
medline:
19
2
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
A series of gatifloxacin-1,2,3-triazole-isatin hybrids 8a-l were designed, synthesized, and screened for their in vitro antimycobacterial activity as well as cytotoxicity toward Chinese Hamster Ovary (CHO) cells. The synthesized hybrids showed considerable activity against MTB H
Identifiants
pubmed: 31441087
doi: 10.1002/ardp.201900135
doi:
Substances chimiques
Antitubercular Agents
0
Triazoles
0
Isatin
82X95S7M06
Gatifloxacin
L4618BD7KJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1900135Informations de copyright
© 2019 Deutsche Pharmazeutische Gesellschaft.